Active Surveillance for Men with Intermediate Risk Prostate Cancer

Uro-Oncology

Personalized Biopsy Schedules Based on Risk of Gleason Upgrading for Low-Risk Prostate Cancer Active Surveillance Patients

BJU Int.

Tomer A, Nieboer D, Roobol MJ, Bjartell A, Steyerberg EW, Rizopoulos D, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium

doi: 10.1111/bju.15136.

Uro-Oncology

Active Surveillance of Prostate Cancer is a Viable Option in Men Younger Than 60 Years

J Urol.

Salari K, Kuppermann D, Preston MA, Dahl DM, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS

doi: 10.1097/JU.

Uro-Oncology

Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS)

J Urol.

Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW

doi: 10.1016/j.juro.2018.07.065.

Uro-Oncology

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes

Eur Urol.

Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y

doi: 10.1016/j.eururo.2018.01.017.

Uro-Oncology

Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer.

J Urol.

Frye TP, George AK, Kilchevsky A, Maruf M, Siddiqui MM, Kongnyuy M, Muthigi A, Han H, Parnes HL, Merino M, Choyke PL, Turkbey B, Wood B, Pinto PA

doi: 10.1016/j.juro.2016.08.109.

Further Publications UrologyFurther Publications Gynecology

A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance

Prostate.

Jarrard D, Filon M, Huang W, Havighurst T, DeShong K, Kim K, Konety BR, Saltzstein D, Mukhtar H, Wollmer B, Suen C, House MG, Parnes HL, Bailey HH

doi: 10.1002/pros.24076.

Uro-Oncology

Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities

Prostate.

Dee EC, Nezolosky MD, Chipidza FE, Arega MA, Butler SS, Sha ST, Mahal BA, Nguyen PL, Yang DD, Muralidhar V

doi: 10.1002/pros.24041.

Uro-OncologyPregnancy and Childbirth

Qualitative study on decision-making by prostate cancer physicians during active surveillance

BJU Int.

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E

doi: 10.1111/bju.13651.

Uro-Oncology

Prostate Health Index and Multiparametric MRI to Predict Prostate Cancer Grade Reclassification in Active Surveillance

BJU Int.

Schwen ZR, Mamawala M, Tosoian JJ, Druskin SC, Ross AE, Sokoll LJ, Epstein JI, Carter HB, Gorin MA, Pavlovich CP

doi: 10.1111/bju.15101.

Related content

Personalized Biopsy Schedules Based on Risk of Gleason Upgrading for Low-Risk Prostate Cancer Active Surveillance Patients

Active Surveillance of Prostate Cancer is a Viable Option in Men Younger Than 60 Years

Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS)

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes

Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer.

A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance

Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities

Qualitative study on decision-making by prostate cancer physicians during active surveillance

Prostate Health Index and Multiparametric MRI to Predict Prostate Cancer Grade Reclassification in Active Surveillance